Arrowhead announces offerings of convertible senior notes and common stock

Arrowhead (ARWR) Pharmaceuticals announced its intention to offer, subject to market and other conditions, $500M aggregate principal amount of convertible senior notes due 2032 and $200M of common stock in separate public offerings registered under the Securities Act of 1933, as amended. The completion of the note offering will not be contingent on the completion of the common stock offering, and the completion of the common stock offering will not be contingent on the completion of the note offering. J.P. Morgan and Jefferies are acting as joint book-running managers for the note offering, and Jefferies and J.P. Morgan are acting as joint book-running managers for the common stock offering.